Latin American Cooperative Oncology Group — Biomedical Watch V2

Traitements1programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

1

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Datopotamab deruxtecanThis is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations. Eligible patients will receive a combination of Datopotamab-deruxtecan, Carboplatin, and Pembrolizumab every three weeks for four cycles, followed by maintenance therapy with Datopotamab-deruxtecan and Pembrolizumab until disease progression or intolerable toxicity. Patients with intracranial progression but no systemic progression may receive stereotactic radiosurgery and continue treatment based on the investigator's decision.	Cancer	Phase 2	Ralentissement de la progression	Brazil	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Pembrolizumab	Cancer	Phase 2	NCT06822543	TROPICAL-1 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.